PDF(Pubmed)
Abstract：
OBJECTIVE: To investigate the expression of nuclear receptor subfamily 1 group D member 1 (NR1D1) and nuclear receptor subfamily 2 group E Member 3 (NR2E3) in retinoblastoma (RB) and their correlation with the clinical and pathological features of RB.
METHODS: Immunohistochemical (IHC) assays were performed to detect and evaluate the expression levels of NR1D1 and NR2E3 in paraffin-embedded tissue samples. The relationship between the expression levels and clinicopathological characteristics of RB patients was analyzed using the χ2 test or Fisher exact test.
RESULTS: A total of 51 RB patients were involved in this research. The expression levels of NR1D1 (P = 0.004) and NR2E3 (P = 0.024) were significantly lower in RB tumor tissues than in normal retina. The expression levels of NR1D1 and NR2E3 were less positive in RB patients with advanced stages (P = 0.007, P = 0.015), choroidal infiltration (P = 0.003, P = 0.029), and optic nerve infiltration (P = 0.036, P = 0.003). In addition, a low expression level of NR2E3 was associated with high-risk pathology (P = 0.025) and necrosis (P = 0.035) of RB tissues.
CONCLUSIONS: The expression levels of NR1D1 and NR2E3 were decreased in RB and closely associated with the clinical stage and high invasion of the disease. These findings provide new insights into the mechanism of RB progression and suggest that NR1D1 and NR2E3 could be potential targets for treatment strategies.
METHODS: Immunohistochemical (IHC) assays were performed to detect and evaluate the expression levels of NR1D1 and NR2E3 in paraffin-embedded tissue samples. The relationship between the expression levels and clinicopathological characteristics of RB patients was analyzed using the χ2 test or Fisher exact test.
RESULTS: A total of 51 RB patients were involved in this research. The expression levels of NR1D1 (P = 0.004) and NR2E3 (P = 0.024) were significantly lower in RB tumor tissues than in normal retina. The expression levels of NR1D1 and NR2E3 were less positive in RB patients with advanced stages (P = 0.007, P = 0.015), choroidal infiltration (P = 0.003, P = 0.029), and optic nerve infiltration (P = 0.036, P = 0.003). In addition, a low expression level of NR2E3 was associated with high-risk pathology (P = 0.025) and necrosis (P = 0.035) of RB tissues.
CONCLUSIONS: The expression levels of NR1D1 and NR2E3 were decreased in RB and closely associated with the clinical stage and high invasion of the disease. These findings provide new insights into the mechanism of RB progression and suggest that NR1D1 and NR2E3 could be potential targets for treatment strategies.
摘要：
目的：探讨核受体亚家族1组D成员1(NR1D1)和核受体亚家族2组E成员3(NR2E3)在视网膜母细胞瘤(RB)中的表达及其与RB临床病理特征的关系。
方法：进行免疫组织化学（IHC）测定以检测和评估石蜡包埋组织样品中NR1D1和NR2E3的表达水平。采用χ2检验或Fisher精确检验分析RB患者的表达水平与临床病理特征之间的关系。
结果：共有51例RB患者参与了这项研究。NR1D1（P=0.004）和NR2E3（P=0.024）在RB肿瘤组织中的表达水平明显低于正常视网膜。NR1D1和NR2E3在晚期RB患者中的阳性表达程度较低(P=0.007,P=0.015),脉络膜浸润(P=0.003,P=0.029),视神经浸润(P=0.036,P=0.003)。此外,NR2E3的低表达水平与RB组织的高风险病理(P=0.025)和坏死(P=0.035)相关。
结论：NR1D1和NR2E3在RB中的表达水平降低，并与疾病的临床分期和高侵袭性密切相关。这些发现为RB进展的机制提供了新的见解，并表明NR1D1和NR2E3可能是治疗策略的潜在靶标。
方法：进行免疫组织化学（IHC）测定以检测和评估石蜡包埋组织样品中NR1D1和NR2E3的表达水平。采用χ2检验或Fisher精确检验分析RB患者的表达水平与临床病理特征之间的关系。
结果：共有51例RB患者参与了这项研究。NR1D1（P=0.004）和NR2E3（P=0.024）在RB肿瘤组织中的表达水平明显低于正常视网膜。NR1D1和NR2E3在晚期RB患者中的阳性表达程度较低(P=0.007,P=0.015),脉络膜浸润(P=0.003,P=0.029),视神经浸润(P=0.036,P=0.003)。此外,NR2E3的低表达水平与RB组织的高风险病理(P=0.025)和坏死(P=0.035)相关。
结论：NR1D1和NR2E3在RB中的表达水平降低，并与疾病的临床分期和高侵袭性密切相关。这些发现为RB进展的机制提供了新的见解，并表明NR1D1和NR2E3可能是治疗策略的潜在靶标。
